Advertisement

Topics

DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer

10:34 EDT 11 Jun 2018 | OncLive

The use of PARP inhibitors in patients with a variety of tumor types is backed by a growing body of research, and there is now strong justification for clinical trials of these agents in patients with prostate cancer.

Original Article: DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer

NEXT ARTICLE

More From BioPortfolio on "DNA Repair Defects Are Strong Targets for Therapeutic Development in Prostate Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...